Transcode Therapeutics Stock Buy Hold or Sell Recommendation
| RNAZ Stock | USD 10.36 0.30 2.81% |
Given the investment horizon of 90 days and your complete indifference towards market risk, our recommendation regarding Transcode Therapeutics is 'Strong Hold'. A buy or sell recommendation is an automated directive regarding whether to purchase or sell Transcode Therapeutics given historical horizon and risk tolerance. When we issue a 'buy' or 'sell' recommendation for Transcode Therapeutics, the advice is generated through an automated system that utilizes algorithms and statistical models.
Check out Transcode Therapeutics Analyst Recommendation to compare Macroaxis Buy or Sell Recommendation with the current analyst consensus. To check ratings for multiple equity instruments, please use the Instant Ratings tool. For more information on how to buy Transcode Stock please use our How to Invest in Transcode Therapeutics guide. In addition, we conduct extensive research on individual companies such as Transcode and provide practical buy, sell, or hold advice based on investors' investing horizon and their risk tolerance towards Transcode Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation.
Transcode |
Execute Transcode Therapeutics Buy or Sell Advice
The Transcode recommendation should be used to complement the buy-or-sell advice compiled from the current analysts' consensus on Transcode Therapeutics. Macroaxis does not own or have any residual interests in Transcode Therapeutics or other equities on which the buy-or-sell advice is provided. Please provide your input below to execute Transcode Therapeutics' advice using the current market data and latest reported fundamentals.
Time Horizon
Risk Tolerance
 |  |
Strong Hold
Market Performance | Insignificant | Details | |
Volatility | Risky | Details | |
Hype Condition | Over hyped | Details | |
Current Valuation | Undervalued | Details | |
Odds Of Distress | Very High | Details | |
Economic Sensitivity | Hyperactively responds to market trends | Details | |
Investor Sentiment | Impartial | Details | |
Analyst Consensus | Buy | Details | |
Financial Strenth (F Score) | Frail | Details | |
Financial Leverage | Not Rated | Details | |
Reporting Quality (M-Score) | Unlikely Manipulator | Details |
Transcode Therapeutics Trading Alerts and Improvement Suggestions
| Transcode Therapeutics is way too risky over 90 days horizon | |
| Transcode Therapeutics appears to be risky and price may revert if volatility continues | |
| Transcode Therapeutics has a very high chance of going through financial distress in the upcoming years | |
| Net Loss for the year was (18.55 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Transcode Therapeutics currently holds about 13.45 M in cash with (18.07 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.04. | |
| Transcode Therapeutics has a frail financial position based on the latest SEC disclosures | |
| Latest headline from finance.yahoo.com: TransCode Therapeutics, Inc. Announces Adjournment of Special Meeting and Information for Adjourned Special Meeting |
Transcode Therapeutics current analysts advice
We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. Transcode analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. Transcode analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.
The consensus estimates and target price estimation comprises individual analyst assessments, and may or may not mutch the Macroaxis buy or sell advice. It is determined by taking an average of all analyst recommendations and classifying them as Strong Buy, Buy, Hold, or Sell.
Transcode Therapeutics Returns Distribution Density
The distribution of Transcode Therapeutics' historical returns is an attempt to chart the uncertainty of Transcode Therapeutics' future price movements. The chart of the probability distribution of Transcode Therapeutics daily returns describes the distribution of returns around its average expected value. We use Transcode Therapeutics price's Value At Risk and its Upside Potential as a relative measure of the distribution. The graph of the distribution of Transcode Therapeutics returns is essential to provide solid investment advice for Transcode Therapeutics.
| Mean Return | 0.39 | Value At Risk | -15.49 | Potential Upside | 28.00 | Standard Deviation | 14.63 |
Return Density |
| Distribution |
Investment risk management requires an estimate of the probability of extreme price changes. Therefore, the correct representation of the distribution of Transcode Therapeutics historical returns presented in an easy-to-digest graphical form helps investors and money managers understand the risk-reward trade-off of different investement strategies.
Transcode Stock Institutional Investors
Have you ever been surprised when a price of an equity instrument, such as Transcode Therapeutics, soars without any apparent reason? This usually happens because many institutional investors are aggressively trading Transcode Therapeutics back and forth among themselves.
| Shares | First Personal Financial Services Inc | 2024-09-30 | 0.0 | Ubs Group Ag | 2024-09-30 | 0.0 | Citadel Advisors Llc | 2024-09-30 | 0.0 | Virtu Financial Llc | 2024-09-30 | 0.0 | Two Sigma Securities, Llc | 2024-09-30 | 0.0 | Geode Capital Management, Llc | 2024-09-30 | 121.8 K | Jane Street Group Llc | 2024-09-30 | 39.7 K | Captrust Financial Advisors | 2024-09-30 | 16.2 K | Morgan Stanley - Brokerage Accounts | 2024-09-30 | 10 K | Tower Research Capital Llc | 2024-09-30 | 6.5 K | Fmr Inc | 2024-09-30 | 175 |
Transcode Therapeutics Cash Flow Accounts
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 (projected) | ||
| Change In Cash | 623.5K | 20.0M | (15.9M) | (2.2M) | (2.0M) | (1.9M) | |
| Net Income | (2.3M) | (6.8M) | (17.6M) | (18.5M) | (16.7M) | (15.9M) | |
| End Period Cash Flow | 828.0K | 20.8M | 5.0M | 2.8M | 3.2M | 5.5M | |
| Free Cash Flow | (493.0K) | (5.5M) | (15.9M) | (18.1M) | (16.3M) | (15.5M) | |
| Other Non Cash Items | 1.5M | 39.5K | (891.0K) | (1.3B) | (1.2B) | (1.1B) |
Transcode Therapeutics Greeks
Most traded equities are subject to two types of risk - systematic (i.e., market) and unsystematic (i.e., nonmarket or company-specific) risk. Unsystematic risk is the risk that events specific to Transcode Therapeutics or Biotechnology sector will adversely affect the stock's price. This type of risk can be diversified away by owning several different stocks in different industries whose stock prices have shown a small correlation to each other. On the other hand, systematic risk is the risk that Transcode Therapeutics' price will be affected by overall stock market movements and cannot be diversified away. So, no matter how many positions you have, you cannot eliminate market risk. However, you can measure a Transcode stock's historical response to market movements and buy it if you are comfortable with its volatility direction. Beta and standard deviation are two commonly used measures to help you make the right decision.
α | Alpha over Dow Jones | 0.37 | |
β | Beta against Dow Jones | 4.69 | |
σ | Overall volatility | 15.08 | |
Ir | Information ratio | 0.03 |
Transcode Therapeutics Volatility Alert
Transcode Therapeutics is showing large volatility of returns over the selected time horizon. Understanding different market volatility trends often help investors to time the market. Properly using volatility indicators enable traders to measure Transcode Therapeutics' stock risk against market volatility during both bullish and bearish trends. The higher level of volatility that comes with bear markets can directly impact Transcode Therapeutics' stock price while adding stress to investors as they watch their shares' value plummet. This usually forces investors to rebalance their portfolios by buying different financial instruments as prices fall.Transcode Therapeutics Fundamentals Vs Peers
Comparing Transcode Therapeutics' fundamentals to the average values of its peers is one of the most widely used and accepted methods of equity analyses. It helps to analyze Transcode Therapeutics' direct or indirect competition across all of the common fundamentals between Transcode Therapeutics and the related equities. This way, we can detect undervalued stocks with similar characteristics as Transcode Therapeutics or determine the stocks which would be an excellent addition to an existing portfolio. Peer analysis of Transcode Therapeutics' fundamental indicators could also be used in its relative valuation, which is a method of valuing Transcode Therapeutics by comparing valuation metrics with those of similar companies.
| Better Than Average | Worse Than Average | Compare Transcode Therapeutics to competition |
| Fundamentals | Transcode Therapeutics | Peer Average |
| Return On Equity | -4.9 | -0.31 |
| Return On Asset | -1.29 | -0.14 |
| Current Valuation | 5.49 M | 16.62 B |
| Shares Outstanding | 696.25 K | 571.82 M |
| Shares Owned By Insiders | 7.78 % | 10.09 % |
| Shares Owned By Institutions | 21.40 % | 39.21 % |
| Number Of Shares Shorted | 368.31 K | 4.71 M |
| Price To Book | 4.37 X | 9.51 X |
| EBITDA | (17.97 M) | 3.9 B |
| Net Income | (18.55 M) | 570.98 M |
| Cash And Equivalents | 13.45 M | 2.7 B |
| Cash Per Share | 1.04 X | 5.01 X |
| Total Debt | 450.57 K | 5.32 B |
| Current Ratio | 8.06 X | 2.16 X |
| Book Value Per Share | 3.16 X | 1.93 K |
| Cash Flow From Operations | (18.07 M) | 971.22 M |
| Short Ratio | 0.12 X | 4.00 X |
| Earnings Per Share | 5,572 X | 3.12 X |
| Target Price | 20.0 | |
| Number Of Employees | 8 | 18.84 K |
| Beta | 1.01 | -0.15 |
| Market Capitalization | 7.21 M | 19.03 B |
| Total Asset | 5.17 M | 29.47 B |
| Retained Earnings | (46.42 M) | 9.33 B |
| Working Capital | 964.85 K | 1.48 B |
| Net Asset | 5.17 M |
Note: Acquisition by Robert Dudley of 6607 shares of Transcode Therapeutics at 2.5498 subject to Rule 16b-3 [view details]
Transcode Therapeutics Market Momentum
Traders often use several daily momentume indicators to supplement a more traditional technical analysis when analyzing securities such as Transcode . With many different options, investors must choose the best indicators for them and familiarize themselves with how they work. We suggest combining traditional momentum indicators with more near-term forms of technical analysis such as Accumulation Distribution or Daily Balance Of Power. With their quantitative nature, daily value technical indicators can also be incorporated into your automated trading systems.
About Transcode Therapeutics Buy or Sell Advice
When is the right time to buy or sell Transcode Therapeutics? Buying financial instruments such as Transcode Stock isn't very hard. However, what challenging for most investors is doing it at the right time to beat the market. Proper market timing is something most people cannot do without sophisticated tools, which help to isolate the right opportunities. Macroaxis provides hands-on modules to deliver winning trades and diversify your portfolios on a daily basis. Most of our advising modules are very easy to use and apply.
Please read more on our stock advisor page.
Use Investing Ideas to Build Portfolios
In addition to having Transcode Therapeutics in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Large Cap ETFs Thematic Idea Now
Large Cap ETFs
ETF themes focus on helping investors to gain exposure to a broad range of assets, diversify, and lower overall costs. The Large Cap ETFs theme has 729 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Large Cap ETFs Theme or any other thematic opportunities.
| View All Next | Launch |
Additional Tools for Transcode Stock Analysis
When running Transcode Therapeutics' price analysis, check to measure Transcode Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Transcode Therapeutics is operating at the current time. Most of Transcode Therapeutics' value examination focuses on studying past and present price action to predict the probability of Transcode Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Transcode Therapeutics' price. Additionally, you may evaluate how the addition of Transcode Therapeutics to your portfolios can decrease your overall portfolio volatility.